BSE Live
Dec 04, 16:01Prev. Close
935.90
Open Price
936.55
Bid Price (Qty.)
935.20 (1)
Offer Price (Qty.)
938.00 (16)
NSE Live
Dec 04, 15:59Prev. Close
934.95
Open Price
938.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
935.75 (283)
| Key Financial Ratios of Zydus Lifesciences (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 11.49 | 18.06 | 17.35 | 14.53 | 19.19 | |
| Diluted EPS (Rs.) | 11.49 | 18.06 | 17.35 | 14.53 | 19.19 | |
| Cash EPS (Rs.) | 18.28 | 23.93 | 22.33 | 18.13 | 21.62 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 114.36 | 114.05 | 87.26 | 69.49 | 56.98 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 114.36 | 114.05 | 87.26 | 69.49 | 56.98 | |
| Revenue from Operations/Share (Rs.) | 139.19 | 128.57 | 116.26 | 91.57 | 92.06 | |
| PBDIT/Share (Rs.) | 28.29 | 31.10 | 28.91 | 19.85 | 23.89 | |
| PBIT/Share (Rs.) | 21.49 | 25.25 | 23.65 | 16.21 | 21.04 | |
| PBT/Share (Rs.) | 14.60 | 23.26 | 22.76 | 15.77 | 20.50 | |
| Net Profit/Share (Rs.) | 11.48 | 18.08 | 17.07 | 14.48 | 18.76 | |
| NP After MI And SOA / Share (Rs.) | 11.49 | 18.05 | 17.34 | 14.53 | 18.89 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.32 | 24.18 | 24.86 | 21.67 | 25.94 | |
| PBIT Margin (%) | 15.44 | 19.64 | 20.34 | 17.69 | 22.84 | |
| PBT Margin (%) | 10.49 | 18.09 | 19.57 | 17.21 | 22.26 | |
| Net Profit Margin (%) | 8.24 | 14.06 | 14.67 | 15.81 | 20.38 | |
| NP After MI And SOA Margin (%) | 8.25 | 14.04 | 14.91 | 15.86 | 20.51 | |
| Return on Networth/Equity (%) | 11.33 | 17.80 | 20.30 | 21.37 | 33.93 | |
| Return on Capital Employed (%) | 14.27 | 16.02 | 14.82 | 15.00 | 27.27 | |
| Return on Assets (%) | 4.96 | 7.87 | 9.82 | 9.77 | 18.32 | |
| Total Debt/Equity (X) | 0.68 | 0.69 | 0.58 | 0.71 | 0.37 | |
| Asset Turnover Ratio (%) | 60.17 | 56.06 | 65.89 | 61.60 | 89.34 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.05 | 1.16 | 1.35 | 1.14 | 1.24 | |
| Quick Ratio (X) | 0.72 | 0.79 | 0.96 | 0.80 | 0.85 | |
| Inventory Turnover Ratio (X) | 5.11 | 4.90 | 4.99 | 5.20 | 7.05 | |
| Dividend Payout Ratio (NP) (%) | 60.90 | 19.38 | 0.00 | 22.02 | 29.64 | |
| Dividend Payout Ratio (CP) (%) | 38.25 | 14.64 | 0.00 | 17.60 | 25.75 | |
| Earnings Retention Ratio (%) | 39.10 | 80.62 | 0.00 | 77.98 | 70.36 | |
| Cash Earnings Retention Ratio (%) | 61.75 | 85.36 | 0.00 | 82.40 | 74.25 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 6.44 | 13.36 | 26.59 | 37.21 | 40.80 | |
| Interest Coverage Ratios (Post Tax) (%) | 6.44 | 13.36 | 26.59 | 37.21 | 40.80 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 34,761.94 | 43,382.44 | 42,762.46 | 48,946.70 | 34,060.08 | |
| EV/Net Operating Revenue (X) | 2.44 | 3.30 | 3.59 | 5.22 | 3.61 | |
| EV/EBITDA (X) | 12.00 | 13.62 | 14.44 | 24.08 | 13.92 | |
| MarketCap/Net Operating Revenue (X) | 1.92 | 2.70 | 3.26 | 4.84 | 3.44 | |
| Retention Ratios (%) | 39.09 | 80.61 | 0.00 | 77.97 | 70.35 | |
| Price/BV (X) | 2.64 | 3.42 | 4.43 | 6.52 | 5.69 | |
| Price/Net Operating Revenue | 1.92 | 2.70 | 3.26 | 4.84 | 3.44 | |
| Earnings Yield | 0.04 | 0.05 | 0.05 | 0.03 | 0.06 |
28.11.2025
Zydus Lifesciences shares gain on tentative USFDA approval for Empagliflozin, Linagliptin tablets
28.11.2025
26.11.2025
14.11.2025
12.11.2025
Zydus Life Standalone September 2025 Net Sales at Rs 2,871.20 crore, up 9.56% Y-o-Y
07.11.2025
Zydus Life Consolidated September 2025 Net Sales at Rs 6,123.20 crore, up 16.92% Y-o-Y
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
24.06.2025
Zydus Life Consolidated March 2025 Net Sales at Rs 6,527.90 crore, up 17.96% Y-o-Y
12.07.2023
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
08.07.2022
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
13.01.2022
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
06.10.2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher